EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Efficacy and Safety of Biologic Therapies for Uncontrolled Asthma: An Overview of Systematic Reviews

Ronaldo José Faria iD, Patrícia Silva Bazoni iD, Jéssica Barreto Ribeiro Dos Santos iD, Erica Tatiane da Silva iD, Michael Ruberson Ribeiro da Silva iD

Pediatric Pulmonology · 2026-07 · 61 (7)

DOI: 10.1002/ppul.71727 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pediatric Pulmonology, online erschienen am 07.07.2026. Verfasst von Ronaldo José Faria und 4 weiteren Autor:innen. Beteiligte Einrichtung: Federal University of Espírito Santo, Postgraduate Program in Pharmaceutical Assistance, Alegre, Brazil. Hauptthemen laut MEDLINE: Asthma, Anti-Asthmatic Agents, Biological Therapy. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Asthma is a heterogeneous inflammatory disease that can cause substantial morbidity, reduced quality of life, and socioeconomic burden when uncontrolled. Biologic therapies have become central to the management of moderate‐to‐severe asthma by targeting specific inflammatory pathways.

Methods

This overview of systematic reviews synthesized evidence on the efficacy and safety of biologic agents for uncontrolled asthma. Searches were conducted in Medline (PubMed), Embase, LILACS, Web of Science, and the Cochrane Library using MeSH and Emtree terms structured according to the PICOT framework. Systematic reviews with meta‐analyses or network meta‐analyses comparing omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, and tezepelumab were included.

Results

In indirect comparisons, dupilumab and tezepelumab were associated with more favorable outcomes in reducing the annualized exacerbation rate (AER) than benralizumab, mepolizumab, and reslizumab in severe uncontrolled asthma. In eosinophilic asthma, indirect evidence suggested more favorable outcomes with mepolizumab, tezepelumab, and dupilumab across eosinophil‐defined subgroups (≥ 400 cells/μL, ≥ 300 cells/μL, ≥ 150 cells/μL, and < 150 cells/μL). In corticosteroid‐dependent asthma, benralizumab and dupilumab were associated with more favorable outcomes in selected comparisons. For lung function (FEV 1 ), indirect evidence suggested more favorable outcomes with dupilumab. Regarding asthma control (ACQ), more favorable outcomes were observed with mepolizumab in specific comparisons. Regarding quality of life (AQLQ), more favorable outcomes were observed with omalizumab and tezepelumab in the general and eosinophilic asthma populations, respectively. One indirect comparison suggested lower odds of serious adverse events with mepolizumab.

Conclusion

The available evidence suggests that biologic therapies may be effective and generally safe options for uncontrolled asthma, although the methodological quality of most included reviews was critically low. These findings support individualized treatment guided by biomarkers and clinical characteristics and highlight the need for standardized, methodologically rigorous future studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaAnti-Asthmatic AgentsBiological TherapyHumansAntibodies, Monoclonal, HumanizedOmalizumabTreatment OutcomeSystematic Reviews as TopicQuality of Life

Stichwörter der Autor:innen

evidence‐based medicinemonoclonal antibodiesprecision medicinesevere asthmatype 2 inflammation

Substanzen

Anti-Asthmatic AgentsAntibodies, Monoclonal, HumanizedmepolizumabOmalizumabreslizumabdupilumabbenralizumab

Autor:innen und Institutionen

  • Federal University of Espírito Santo, Postgraduate Program in Pharmaceutical Assistance, Alegre, Brazil.
  • Federal University of Espírito Santo, Group on Health Technology Assessment and Economy, Alegre, Brazil.
  • Program of Evidence for Health Policy and Technologies, Oswaldo Cruz Foundation- Fiocruz Brasília, Brasília, Brazil.

ORCID-Profile: Ronaldo José Faria, Patrícia Silva Bazoni, Jéssica Barreto Ribeiro Dos Santos, Erica Tatiane da Silva, Michael Ruberson Ribeiro da Silva

Zitieren

APA

Faria, R. J., Bazoni, P. S., Santos, J. B. R. D., Silva, E. T. D., & Silva, M. R. R. D. (2026). Efficacy and Safety of Biologic Therapies for Uncontrolled Asthma: An Overview of Systematic Reviews. Pediatric Pulmonology, 61(7). https://doi.org/10.1002/ppul.71727

Vancouver

Faria RJ, Bazoni PS, Santos JBRD, Silva ETD, Silva MRRD. Efficacy and Safety of Biologic Therapies for Uncontrolled Asthma: An Overview of Systematic Reviews. Pediatric Pulmonology. 2026;61(7). doi:10.1002/ppul.71727

BibTeX
@article{Faria2026,
  author = {Faria, Ronaldo José and Bazoni, Patrícia Silva and Santos, Jéssica Barreto Ribeiro Dos and Silva, Erica Tatiane da and Silva, Michael Ruberson Ribeiro da},
  title = {Efficacy and Safety of Biologic Therapies for Uncontrolled Asthma: An Overview of Systematic Reviews},
  journal = {Pediatric Pulmonology},
  year = {2026},
  volume = {61},
  number = {7},
  doi = {10.1002/ppul.71727}
}
Kostenlos starten →